Accordingly, several PDE5 inhibitors have been developed and applied for the treatment of erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension (PAH) (Papapetropoulos et al. 2015). This evidence concerns the gene PDE5A and pulmonary arterial hypertension.